Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18.
Nineteen topics were selected as major clinical research advances in gynecologic oncology in 2018. For cervical cancer, the importance of human papillomavirus (HPV) testing alone as primary cervical cancer screening method and negative survival impact of minimally invasive surgery in early-stage cervical cancer were addressed. For ovarian cancer, cost-effectiveness of genetic testing to prevent cancer, use of analgesics and oral pill to reduce cancer risk, efficacy of secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, update in the use of poly (ADP-ribose) polymerase inhibitor, and efficacy of anti-angiogenic targeted treatments, including bevacizumab and tyrosine kinase inhibitors, were reviewed. For corpus cancer, sentinel lymph node mapping technique, adjuvant therapy in high-risk endometrial cancer (PORTEC-3), and targeted therapy in recurrent disease were covered. For the field of radiation oncology, survival outcomes of chemoradiation compared with chemotherapy alone in metastatic cervical cancer and new findings regarding the use of neoadjuvant chemotherapy in locally advanced cervical cancer were introduced. Lastly, for breast cancer, the use of talazoparib in patients with germline mutation, ovarian suppression for premenopausal patients, adjuvant chemotherapy guided by 21-gene assay, and combination therapy of atezolizumab and nab-paclitaxel for triple-negative cancer as well as promising overall survival results of palbociclib and fulvestrant in advanced breast cancer were briefly mentioned.
19 个主题被选为 2018 年妇科肿瘤学的主要临床研究进展。对于宫颈癌，单独的人乳头瘤病毒（HPV）检测作为主要的宫颈癌筛查方法的重要性，以及早期宫颈癌微创手术的阴性生存影响得到了强调。对于卵巢癌，预防癌症的基因检测的成本效益、镇痛药和口服药丸在降低癌症风险中的应用、二次细胞减灭术和腹腔内热化疗的疗效、多聚（ADP-核糖）聚合酶抑制剂的使用更新，以及抗血管生成靶向治疗的疗效，包括贝伐单抗和酪氨酸激酶抑制剂，都进行了回顾。对于子宫体癌，涵盖了前哨淋巴结绘图技术、高危子宫内膜癌（PORTEC-3）的辅助治疗，以及复发性疾病的靶向治疗。在放射肿瘤学领域，介绍了转移性宫颈癌中放化疗与单纯化疗的生存结果，以及新发现的局部晚期宫颈癌中应用新辅助化疗的情况。最后，对于乳腺癌，讨论了用于种系突变患者的 talazoparib、绝经前患者的卵巢抑制、基于 21 基因检测的辅助化疗，以及 atezolizumab 和 nab-paclitaxel 联合治疗三阴性乳腺癌，以及 palbociclib 和 fulvestrant 在晚期乳腺癌中令人鼓舞的总生存结果。
